How "Blind" Are Double-Blind Placebo-Controlled Trials of Benzodiazepine Hypnotics?
|
|
- Donald Rich
- 6 years ago
- Views:
Transcription
1 Sleep, 18(4): American Sleep Disorders Association and Sleep Research Society How "Blind" Are Double-Blind Placebo-Controlled Trials of Benzodiazepine Hypnotics? Charles M. Morin, Cheryl Colecchi, Doug Brink, Manual Astruc, James Mercer and Stephanie Remsberg Medical College of Virginia/Virginia Commonwealth University, Richmond, Virginia, U.S.A. Summary: This study examined the accuracy of insomnia patients and their treating physicians in whether an active hypnotic drug or a placebo was given in treatment. Forty older adults with primary insomnia were randomly assigned to either an active (temazepam) or a placebo condition using a double-blind strategy. Ratings of treatment conditions were obtained at I week (early treatment), 4 weeks (midtreatment), and 8 weeks (late treatment). Patients were able to accurately discriminate (beyond chance levels) between the active and placebo medications at the early (76.9% accuracy) and late treatment assessment timepoints (78.1% accuracy), but not at mid treatment (51.5% accuracy). Therapists, however, were able to make accurate discriminations at the late treatment assessment timepoint only (80% accuracy); early (69.2% accuracy) and midtreatment (47.2% accuracy) s did not exceed chance levels. Patients who had used hypnotic drugs prior to this trial were more accurate in their judgments of treatment conditions than those without prior exposure. The findings raise an important issue about the internal validity of the double-blind strategy, which may in fact be only a single-blind procedure. The double-blind procedure is the standard method used in psychopharmacologic studies to control for nonspecific effects, such as those caused by patient expectations, experimenter bias (e.g. instructional demands) and treatment credibility (1,2). It is generally assumed that the effects of these potentially confounding variables will be minimized or eliminated by withholding the nature ofthe treatment condition from the patient and therapist (i.e. whether an active or placebo is given). Furthermore, this strategy presumes that both the patient and therapist are unable to distinguish on their own the type of treatment given. This presumption, however, has never been evaluated empirically in controlled trials of hypnotic drugs, raising an important issue about the internal validity ofthe doubleblind strategy. Several controlled studies of other psychoactive drugs recently have questioned the validity of the doubleblind procedure (3-7). For instance, in clinical trials of lithium, imipramine and nicotine drugs, participants were able to determine beyond chance levels whether the medication received was active or a pla- Accepted for publication November Address correspondence and reprint requests to Charles M. Morin, Ph.D., Universite Laval, Ecole de Psychologie, Ste-Foy, Quebec, Canada GlK 7P cebo. Because the s were obtained at the end of treatment, it was impossible to determine whether the s were influenced by treatment outcome or vice versa. Margraf et al. (8) addressed this problem in their study of patients with panic disorders by having patients and therapists rate halfway through treatment (at 4 weeks) whether alprazolam, imipramine or a placebo was given. It was found that both patients and therapists were accurate in their s halfway through treatment. However, the authors cautioned that treatment effects might have already been evident this early in treatment, thereby contributing to the accuracy of s. They pointed out the need for future studies to assess patients' and physicians' s about the treatment condition as early as the 1 st week of treatment. The assessment of the double-blind method early on in treatment is especially important in insomnia research because, unlike some other psychotropic medications (e.g. antidepressant) whose therapeutic effects may be delayed, hypnotic drugs have more immediate effects that may also dissipate over time (9,10). Also, because sleep improvements as well as side effects may change over time, it is important to evaluate the double-blind procedure at repeated intervals during the course of treatment. In addition to clinical response and side effects, other factors (e.g. prior experience with
2 HOW "BLIND" ARE DOUBLE-BLIND TRIALS? 241 -, hypnotic drugs) that may mediate patients' accuracy in distinguishing between a placebo and an active sleep medication should be evaluated_ The purpose of the present study was to examine whether insomnia patients and their physicians were really "blind" to treatment conditions involving an active sleep medication or a placebo. To determine the extent to which treatment outcomes impact the individual's s, patients and therapists were asked to determine whether an active or inactive medication was given at three assessment points during the course of an 8-week clinical trial. Due to the more immediate therapeutic effects and side effects of hypnotic medications, it was expected that patients and physicians would be able to determine whether they received an active or a placebo drug as early as after the 1st week of treatment. Subjects METHODS Data collection was part of a larger study comparing the clinical efficacy of cognitive-behavior therapy and pharmacotherapy for late-life insomnia (11). Participants were community-residing elderly who responded to newspaper advertisements. They were initially screened over the phone. After this initial screening, each participant underwent a multistep evaluation: (a) a clinical interview with a board-certified sleep specialist, (b) a physical examination, (c) a psychological evaluation and (d) 3 consecutive nights of polysomnography. All participants met criteria for primary insomnia (12), which was mostly of the psychophysiological subtype (13). Minimal entry criteria were that subjects reported chronic (i.e. greater than a 6-month duration) difficulties maintaining sleep, which was defined as wake after sleep onset greater than 30 minutes per night for more than 3 nights per week. Subjects were excluded if there was evidence of significant sleep apnea (respiratory disturbance index> 15) or periodic limb movements (PLM) during sleep (PLM with arousal > 15). All subjects were free from psychotropic drugs for at least 2 weeks prior to entering the study. A total of 78 patients participated in the study; patients were randomly assigned to one of the four following conditions: 18 to cognitive-behavior therapy, 20 to pharmacotherapy (temazepam), 20 to combined cognitivebehavior therapy and pharmacotherapy, and 20 to a drug placebo. The present study considers only patients in the active and placebo medication conditions. Of the 40 participants, 16 were male and 24 were female. Their mean age was 65 years (SD = 6.7 years) and their average education level was 14.9 years (SD = 2.5 years). They were predominantly married (67.5%). Fifty percent were retired, and 37.5% were employed (10% were homemakers and 2.5% unemployed). The average duration of insomnia was 16.5 years (SD = 15.5 years). Thirty-one (78%) of the 40 subjects had previously used prescribed (n = 25) or over-the-counter sleep medications (n = 6); nine subjects had never used sleep aids. Of those who had used a prescribed hypnotic medications four had specifically used temazepam. Procedures Subjects were randomly assigned to the active or placebo condition. Treatment was provided in a double-blind fashion such that neither the patients nor the therapists were informed of whether an active or placebo drug was involved for any given patient. The patients were informed about the four treatment conditions being compared and were told that their chance of being assigned to anyone condition was approximately 25%. Pharmacotherapy consisted of temazepam. Patients were all started on 7.5 mg and medication could be increased, based on the patient's subjective response, to a maximum of 30 mg. The dosage could be decreased, based on side effects, to a minimum dosage of7.5 mg. It was recommended that the patient use the medication 2-3 nights per week, but it was made available for nightly use as needed. The placebo medication consisted of an inert lactose solution. Both active and placebo drugs were provided in identical gelatin capsules filled with an equivalent amount of powder. These capsules were dispensed by the Investigational Drug Pharmacy. Dosages of up to 22.5 mg oftemazepam were included in one capsule. Only those subjects taking 30 mg were given two capsules. Subjects in the placebo condition were given the same feedback regarding dosage of medication and an identical opportunity as those in the active medication condition to increase their dosage to a maximum of 30 mg or two capsules. All treatments lasted 8 weeks. Subjects in both treatment conditions underwent a prescreening psychiatric and medical evaluation by a thirdyear psychiatry resident, who then continued to see each subject once a week for a minute session devoted to reviewing treatment progress, side effects and insomnia symptoms. Urine drug screens for benzodiazepines were conducted at baseline to ensure that subjects were free from these agents and at late treatment to ensure compliance with prescribed medication regimen. At the end of the 8 weeks (i.e. 1 week after the eighth therapy session), all subjects began a 1-2 week tapering schedule. The dosage was gradually decreased to the next lowest level for 2 or more nights. This pattern was repeated until the lowest dosage (7.5 mg) was Sleep. Vol. 18. No
3 242 C. MORIN ET AL. reached. Medication was then discontinued. For example, a subject using 30 mg at the end of treatment would be tapered to 22.5 mg for 2-3 nights, 15 mg for 2-3 nights and 7.5 mg for the last 2-3 nights before discontinuation. This tapering schedule was followed in an identical fashion for subjects in both the active and placebo conditions. Measures Participants and therapists were asked to independently judge whether an active medication or a placebo had been given on three separate occasions: after the 1 st week (early treatment), the 4th week (midtreatment) and the 8th and final week (late treatment). The late treatment assessment occurred at the last treatment session (i.e. 1 week before the tapering schedule began). The patients were asked to make this determination on a treatment evaluation questionnaire, which included several other items. The question read: "Do you think you are receiving (or for therapists, "this patient is receiving") an active sleep medication or a placebo (inactive substance)? Please make a choice even if you're not sure". Responses were: "(a) Active sleep medication" or "(b) Placebo (inactive substance)". At all three assessment points, both therapists and patients were also asked to rate the certainty of their judgment regarding whether an active medication or placebo had been given by answering the following question: "How certain are you that your answer to question 1 (i.e. active or placebo) is correct"? They were instructed to place a mark on a 100-mm visual analog scale anchored at one end by "Not at all certain" and the other end by "Absolutely certain". An additional on an identical visual analog scale was obtained for perceived side effects. The item asked: "To what extent have you experienced side effects as a result of using this sleep medication"? Responses were converted into a metric measurement of the distance of their mark on the continuum. Finally, patients and their therapists were asked to "Rate the degree of change, if any, in your (this patient's) sleep pattern since you (this patient) first enrolled in this treatment program". Ratings were on a scale of 1 to 5; 1 was equal to "Unchanged or worse", 2 to "Slightly improved", 3 to "Improved", 4 to "Much improved", and 5 to "Very much improved". Patients' forms were secured in a sealed envelope to which the therapists did not have access. RESULTS The following research questions were examined: (a) How accurate are insomnia patients and their therapists in identifying treatment conditions (active vs. Sleep, Vol. 18, No.4, 1995 placebo)? (b) Are subjects on active medication more accurate in identifying their treatment than those receiving placebo? (c) Is accuracy in identifying treatment conditions mediated by treatment response, side effects and prior exposure to hypnotic medications? All categorical variables were analyzed with x 2 tests (with Yates corrections for continuity) and continuous variables were analyzed with either t tests or repeatedmeasures analyses of variance (ANOVAs). When multiple comparisons were computed, Bonferroni corrections were applied to correct for inflated Type 1 error. Preliminary analyses Of the 40 patients enrolled in the study, three patients withdrew from the active drug condition and two from the placebo condition, leaving 35 subjects for whom data were available. Because this project was initiated only after some subjects were already beyond their 1 st week of treatment, data were available for only 26 subjects at the early assessment timepoint. Preliminary analyses revealed that the two groups were equivalent on demographic (e.g. age and gender) and clinical variables (e.g. insomnia severity and duration). The percentage of medicated nights for all subjects was 77% (SD = 17.7%) and the average nightly dosage was 20.3 mg (SD = 3.8 mg). There were no significant group differences (active medication vs. placebo) on either the percentage of medicated nights or the average dosage used per night. All active and placebo subjects used medication a minimum of 3 nights per week for the entire duration of treatment. The number of subjects with and without prior use of hypnotic drugs was also equivalent in both conditions. Patients' accuracy s Patients' s of type of treatment received at the three assessment points are shown in Table 1. Patients' s were 76.9% accurate at early treatment assessment, 51.5% accurate at midtreatment and 78.1 % accurate at late treatment. Chi-square tests (actual vs. hypothesized treatment) revealed that observed values significantly exceeded expected values (a 50% chance of correctly) at early treatment assessment [x 2 (1, n = 26) = 5.4, p < 0.02] and at late treatment assessment [x 2 (1, n = 32) = 8.9, p < 0.005], but not at mid treatment. However, the lack of accuracy at the midpoint appears to be related to the type of treatment received, as only the placebo group was less accurate at this time (38.8%) than chance guessing alone. Physicians' accuracy s Physicians' s are displayed in Table 2. Accuracy rates were 69.2% early in treatment, 47.2% at
4 HOW "BLIND" ARE DOUBLE-BLIND TRIALS? 243 midtreatment and 80% at late treatment. Those s were significantly different from expected values (i.e. chance levels) at late treatment only [x 2 (l, n = 30) = 8.8, p < 0.005]. Within the active drug condition, accuracy rates were 58.3%, 35.3% and 85.7% at the three assessment points. Accuracy rates within the placebo condition were 78.6% (early), 57.9% (mid) and 75% (late). Patients' and therapists' certainty s The next set of analyses examined levels of certainty in patients' and therapists' s as a function of actual treatment. A repeated-measures ANOV A was conducted on patients' certainty s, using actual treatment condition as the between-group factor and time of assessment as the within-subject factor. There were no significant group or interaction effects. There was, however, a significant effect for time [F(2,40) = 9.1, p < 0.001]. Post hoc comparisons showed that subjects in both conditions became more certain of their s as treatment progressed over time. A repeated-measures ANOV A on therapists' certainty s revealed identical results. Whereas no significant group or interaction effects were obtained, a significant effect for time [F(2,40) = 20.6, p < 0.001] indicated that therapists also were increasingly more confident about their s of treatment conditions as the intervention unfolded. Factors related to accuracy Several sources of information can be used to identify treatment assignments. In this study, we examined whether treatment response, side effects and prior use of hypnotic medication were related to accurate identification of treatment conditions. Treatment response The first set of analyses sought to determine whether treatment responses (i.e. perceived changes in sleep patterns) were related to accuracy of patients' and therapists' s. Subjects receiving the active medication were compared with those receiving the placebo drug. A repeated-measures ANOV A on patients' s of sleep improvements revealed significant effects for group [F(I,22) = 14.72, p < 0.001], time [F(2,44) = 19.98, p < 0.001] and a nearly significant group x time interaction effect [F(2,44) = 2.61, p = 0.08]. Post hoc comparisons indicated that perceived improvements in sleep patterns were, as expected, significantly greater in the active drug condition than in the placebo group (at mid- and late treatment assessment times only), and that patients in both conditions rated their TABLE 1. Identification of condition: patients' responses Correct responses Incorrect responses n (%) [mean (SD)] n (%) [mean (SD)] Early treatment (n = 26) Active 8 (67) 58.8 (32.9) 4 (33) 34.5 (34.6) Placebo 12 (86) 41.6 (24.4) 2 (14) 3.0 (3.0) Midtreatment (n = 33) Active 10 (67) 71.7 (18.2) 5 (33) 36.8 (28.2) Placebo 7 (39) 64.4 (25.2) 11 (61) 57.2 (21.1) Late treatment (n = 32) Active 15 (94) 76.4 (21.3) 1 (6) 7.0 (0.0) Placebo 10 (63) 74.7 (19.2) 6 (37) 58.5 (16.4) sleep patterns as significantly improved over time (all p values < 0.01). A repeated-measures ANOVA on therapists' s of sleep improvements revealed a significant effect for group [F(l,20) = 7.66, p < 0.02] and time [F(2,40) = 12.70, p < 0.001], but not for the group x time interaction. Therapists rated subjects in the active drug condition as significantly more improved than subjects in the placebo condition, and subjects in both conditions as significantly improved from pre-, to mid-, to late treat~ ment (all p values < 0.01). To examine whether the above results could invalidate the overall treatment outcome findings, we compared perceived improvements in the sleep patterns of those who were accurate with those who were inaccurate in their judgments. There were no significant differences for patients or therapists at any of the three assessment points. It is plausible that some individuals who were re~ ceiving an inadequate dose of the active drug, partic~ ularly in the early phase of treatment, thought they were receiving a placebo. These individuals might be viewed as accurate relative to someone receiving an effective dose. To examine this issue we looked at the TABLE 2. Identification of condition: therapists' response Correct responses Incorrect responses n (%) [mean (SD)] n (%) [mean (SD)] Early treatment (n = 26) Active 7 (58) 36.0 (25.6) 5 (42) 37.4 (29.7) Placebo 11 (79) 35.7 (31.9) 3 (21) 73.0 (16.6) Midtreatment (n = 36) Active 6 (35) 76.8 (8.47) 11 (65) 64.7 (22.8) Placebo 11 (58) 76.1 (19.7) 8 (42) 59.1 (18.2) Late treatment (n = 30) Active 12 (86) 80.1 (22.4) 2 (14) 95.5 (4.5) Placebo 12 (75) 77.5 (25.4) 4 (25) 59.0 (33.2) Sleep, Vol. 18, No.4, 1995
5 244 C. MORIN ET AL. accuracy of a patient's judgment as a function of perceived treatment response within the active drug condition only. Subjects in that condition were divided into two subgroups based on whether they perceived their sleep as improved (self-s of slightly, moderately and much improved) or unimproved (self-s of unchanged or worse). Within the active drug condition, four subjects were inaccurate at the early assessment (two responders and two non responders), five were inaccurate at midtreatment (four responders and one nonresponder), and only one was inaccurate (a nonresponder) at late treatment. When subjects with only slight improvements were considered nonresponders and were combined with those rated as unchanged or worse, a different picture emerged. All but one of the subjects with inaccurate s in the active drug-condition group (i.e. those who thought they were receiving a placebo) were nonresponders. Side effects Subjects receiving the active medication were compared with those receiving the placebo drug for perceived side effects. Repeated-measures ANOVAs on patients' and therapists' s of side effects revealed no significant group, time or group x time interaction effects. Perceived side effects were also compared between subjects who were accurate and those who were inaccurate in identifying their treatment condition, and no significant group differences were obtained for either patients' or therapists' s. Prior use of hypnotic medication To examine the impact of prior exposure to hypnotic medications on accuracy of perception of active versus placebo drugs, patients who previously had used a prescribed hypnotic medication were compared with those who had not. For this analysis, subjects who had used only over-the-counter medications were combined with those who had not used any medications. There was a general trend for subjects with a prior history of hypnotic use to be more accurate than those who had never used hypnotics or those who had used only overthe-counter agents. The percentages of accuracy for the two groups were 80% versus 73% at the early treatment assessment timepoint, 65% versus 31 % at midtreatment and 84% versus 69% at late treatment. Chi-square tests indicated a significant difference in accuracy s between these two groups at midtreatment only [x 2 (1, n = 32) = 5.2, p < 0.05]. Thirteen (65%) of the 20 patients with a prior history of prescribed hypnotic use were accurate, whereas only four (31 %) of 13 without prior use were accurate in judging treatment conditions. DISCUSSION The results showed that insomnia patients were able to accurately determine whether an active benzodiazepine hypnotic or a placebo drug was given as early as 1 week into treatment and at the end of treatment. Patients' s at midtreatment were not different from those expected by chance alone, although this inaccuracy was accounted for primarily by subjects receiving a placebo drug. Prescribing physicians were accurate in their determination of whether an active medication or a placebo was given at the late treatment assessment point only. These findings suggest that the double-blind procedure used in controlled studies of benzodiazepine hypnotics may in fact be only a singleblind method. The temporal fluctuations in accuracy rates over the three assessment phases were somewhat similar for both patients and therapists, at least when the data were collapsed across conditions. Accuracy rates were 77% and 69% at the early treatment assessment timepoint, 52% and 47% at midtreatment, and 78% and 80% at late treatment for patients and therapists, respectively. A different pattern of results seems to emerge, however, when accuracy rates are examined within each treatment condition. For instance, patients in the active drug condition were consistently accurate in identifying their condition across assessment phases, whereas those in the placebo condition showed more fluctuations over time; the midtreatment data were the least accurate for this group. The decline in accuracy s at midtreatment is difficult to explain in light of the increase in certainty s. It is plausible, however, that some nonspecific factors (e.g. therapist attention, expectancy, support) may have temporarily introduced some confounding factors in s of conditions at the midtreatment assessment phase. The therapists were accurate only at the late treatment assessment point, although they appeared to be more accurate at judging a placebo than an active medication in early treatment. Three factors that may account for the failure to maintain blindness were examined in this study: history of hypnotic usage, drug side effects and perceived sleep improvements. First, individuals with previous use of hypnotic medications were more accurate in determining whether they received an active or placebo drug at midtreatment assessment. This finding contrasts with the finding that those on placebo were most inaccurate at midtreatment. Furthermore, the lack of group differences in perceived side effects between active and placebo subjects suggests that this information was not critical in accurately determining treatment conditions. Finally, because perceived improvements in sleep patterns were generally greater in the active Sleep. Vol. 18. No
6 HOW "BLIND" ARE DOUBLE-BLIND TRIALS? 245 medication group than in the placebo condition, therapeutic effects may have been important in accurately determining treatment conditions. The importance of treatment response as a mediating factor of accuracy is further supported by the active drug-group accuracy s, which were highest at late treatment, i.e. after optimal dosage and, presumably, maximal efficacy had been achieved. An important issue raised by the latter results is whether failure to maintain blindness may invalidate the outcome findings from controlled trials. This issue is not as problematic with therapist s, because those s became more accurate only at the end of treatment; thus, it is unlikely that they had a significant influence on treatment outcome. On the other hand, patients were fairly accurate in determining their treatment condition even in the beginning of treatment. Knowledge of whether an active or placebo drug is involved early in treatment could alter patients' expectations and treatment credibility and potentially invalidate the ultimate outcome findings. However, the finding of no significant differences in perceived sleep improvements between patients who were accurate and those who were inaccurate in their s of treatment suggests that the outcome may still be valid even though blindness was not maintained. The dubious nature of presumed double-blind studies poses a serious challenge to the utilization of this strategy (14). The patient's ability to distinguish between an active medication and a placebo could potentially influence compliance as well as treatment outcome. For instance, if patients believe they are receiving a placebo, they may be less inclined to remain in a clinical trial. Although a potential solution to this problem might be to use an "active placebo", i.e. a substance that would mimic some ofthe side effects of the active medication (15), side effects did not appear to play a significant role in identification of treatment conditions in the present study. Future studies need to explore more systematically the type of information subjects in clinical trials use to determine whether they are receiving an active or placebo drug. Examination of other nonspecific factors (e.g. patients' expectations and acceptance of hypnotic drugs, treatment credibility) is also needed to better understand their mediating role on insomnia treatment outcome (16). Acknowledgements: Preparation of this manuscript was supported by grant R29-MH47020 from the National Institutes of Mental Health, Bethesda, MD. REFERENCES I. K1erman GL. Scientific and ethical considerations in the use of placebo controls in clinical trials in psychopharmacology. Psychopharmacol Bull 1986;22: White L, Tursky B, Schwartz GE. Placebo: theory, research, and mechanisms. New York: Guilford Press, Hughes J, Krahn D. Blindness and the validity of the doubleblind procedure. J Clin PsychopharmacoI1985;5: Marini JL, Sheard M, Bridges C, Wagner E. An evaluation of the double-blind design in a study comparing lithium carbonate with placebo. Acta Psychiatr Scan 1976;53: Rabkin JG, Markowith JS, Stewart J, et al. How blind is blind? Assessment of patient and doctor medication guesses in a placebo-controlled trial of imipramine and phenelzine. Psychiatry Res 1986;19: Rickels K, Hesbacher PT, Weise CC, Gray R, Feldman HS. Pills improvement: a study of placebo response in psychoneurotic outpatients. Psychopharmacologia 1970; 16: Stallone F, Mendlewicz J, Fieve R. Double-blind procedure: an assessment in a study oflithium prophylaxis. Psychol Med 1975;5: Margraf J, Ehlers N, Roth WT, et al. How "blind" are doubleblind studies? J Consult Clin PsychoI1991;59: Morin CM, Kwentus JA. Behavioral and pharmacological treatments for insomnia. Ann Behav Med 1988; I 0: Gillin JC, Byerley WE The diagnosis and management of insomnia. N Engl J Med 1990;322: II. Morin CM, Stone J, Maghakian C, Astruc M, Mercer J, Brinks D. Cognitive behavior therapy and pharmacotherapy for latelife insomnia: a placebo-controlled trial. Sleep Res 1993;22: American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC: American Psychiatric Association, Diagnostic Classification Steering Committee, Thorpy, MJ, chairman. International classification of disorders: diagnostic and coding manual. Rochester, MN: American Sleep Disorders Association, Fisher S, Greenberg RP, eds. The limits of biological treatments for psychological distress: comparisons with psychotherapy and placebo. Hillsdale, NJ: Erlbaum, Blumenthal DS, Burke R, Shapiro K. The validity of "identical matching placebos." Arch Gen Psychiatry 1974;31: Morin CM. Insomnia: psychological assessment and management. New York: Guilford Press, Sleep, Vol. 18, No.4, 1995
Definition of Acute Insomnia: Diagnostic and Treatment Implications. Charles M. Morin 1,2. Keywords: Insomnia, diagnosis, definition
Acute Insomnia Editorial 1 Definition of Acute Insomnia: Diagnostic and Treatment Implications Charles M. Morin 1,2 1 Université Laval, Québec, Canada 2 Centre de recherche Université Laval/Robert-Giffard,
More informationSafe Prescribing of Drugs with Potential for Misuse/Diversion
College of Physicians and Surgeons of British Columbia Safe Prescribing of Drugs with Potential for Misuse/Diversion Preamble This document establishes both professional standards as well as guidelines
More informationBenzodiazepines: risks, benefits or dependence
Benzodiazepines: risks, benefits or dependence A re-evaluation Council Report CR 59 January 1997 Royal College of Psychiatrists, London Due for review: January 2002 1 Contents A College Statement 3 Benefits
More informationDrug Review Rozerem (ramelteon)
Drug Review Rozerem (ramelteon) Introduction 1 Ramelteon is a melatonin receptor agonist with affinity for MT 1 and MT 2 and selectivity over the MT 3 receptor. The activity at the MT 1 and MT 2 receptors
More informationProduct: Femmerol. Client: Solutions for Women, LLC 315 North Village Avenue New York, (516)
CLINICAL TRIAL In 2002 the company completed an IRB (Institutional Review Board) Prospective, Randomized, Placebo-Controlled Clinical Trial. In Conclusion: Femmerol is effective in relieving a number of
More informationANXIETY AND DEPRESSIVE NEUROSIS - THEIR RESPONSE TO ANXIOLYTIC AND ANTIDEPRESSANT TREATMENT GURMEET SINGH 1 R. K. SHARMA 2 SUMMARY
Indian Journal of Psychiatry, January 29(1), pp 49-56 ANXIETY AND DEPRESSIVE NEUROSIS - THEIR RESPONSE TO ANXIOLYTIC AND ANTIDEPRESSANT TREATMENT GURMEET SINGH 1 R. K. SHARMA 2 SUMMARY A total of 90 patients
More informationORIGINAL INVESTIGATION. Gregg D. Jacobs, PhD; Edward F. Pace-Schott, MA; Robert Stickgold, PhD; Michael W. Otto, PhD
ORIGINAL INVESTIGATION Cognitive Behavior Therapy and Pharmacotherapy for Insomnia A Randomized Controlled Trial and Direct Comparison Gregg D. Jacobs, PhD; Edward F. Pace-Schott, MA; Robert Stickgold,
More informationCognitive-Behavioral Assessment of Depression: Clinical Validation of the Automatic Thoughts Questionnaire
Journal of Consulting and Clinical Psychology 1983, Vol. 51, No. 5, 721-725 Copyright 1983 by the American Psychological Association, Inc. Cognitive-Behavioral Assessment of Depression: Clinical Validation
More informationApplication of Psychotropic Drugs in Primary Care
Psychotropic Drugs Application of Psychotropic Drugs in Primary Care JMAJ 47(6): 253 258, 2004 Naoshi HORIKAWA Professor, Department of Psychiatry, Tokyo Women s Medical University Abstract: The incidence
More informationMAPS Study MP-10 1 Study Synopsis UK April 18, 2011
MAPS Study MP-10 1 Study Synopsis A Randomized, Triple-Blind, Phase 2 Pilot Study with an Open-Label Lead-in Comparing 3 Different Doses of MDMA in Conjunction with Manualized Psychotherapy in 20 Subjects
More informationA randomized controlled clinical trial of Citalopram versus Fluoxetine in children and adolescents with obsessive-compulsive disorder (OCD)
Eur Child Adolesc Psychiatry (2009) 18:131 135 DOI 10.1007/s00787-007-0634-z ORIGINAL CONTRIBUTION Javad Alaghband-Rad Mitra Hakimshooshtary A randomized controlled clinical trial of Citalopram versus
More informationExplanatory Attributions of Anxiety and Recovery in a Study of Kava
THE JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE Volume 10, Number 3, 2004, pp. 556 559 Mary Ann Liebert, Inc. Explanatory Attributions of Anxiety and Recovery in a Study of Kava KURIAN C. ABRAHAM,
More informationWhat Is the Moment of Sleep Onset for Insomniacs?
Sleep, 6(1): 10-\5 1983 Raven Press, New York What Is the Moment of Sleep Onset for Insomniacs? Peter Rauri and Elaine Olmstead Dartmouth Medical School, Hanover, New Hampshire, U,S,A, Summary: Subjective
More informationBenzodiazepines: Comparative Effectiveness and Strategies for Discontinuation. Ann M. Hamer, PharmD, BCPP Rural Oregon Academic Detailing Project
Benzodiazepines: Comparative Effectiveness and Strategies for Discontinuation Ann M. Hamer, PharmD, BCPP Rural Oregon Academic Detailing Project This project is funded through a grant from the Pew Charitable
More informationGerman Journal of Psychiatry 2000; 3
Reprinted from the German Journal of Psychiatry http://www.gjpsy.uni-goettingen.de ISSN 1433-1055 Assuring the Quality of the Utilization of Psychoactive Medication by People with Mental Retardation and
More informationOpioids in the Management of Chronic Pain: An Overview
Opioids in the Management of Chronic Pain: An Overview Appropriate treatment of chronic pain may include both pharmacologic and non-pharmacologic modalities. The Board realizes that controlled substances,
More informationTreatment of AD with Stabilized Oral NADH: Preliminary Findings
MS # 200 000 128 Treatment of AD with Stabilized Oral NADH: Preliminary Findings G.G. Kay, PhD, V. N. Starbuck, PhD and S. L. Cohan, MD, PhD Department of Neurology, Georgetown University School of Medicine
More informationSupplementary Online Content
Supplementary Online Content Subotnik KL, Casaus LR, Ventura J, et al. Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia:
More informationClonazepam Augmentation Of Paroxetine In The Treatment Of Panic Disorder: A One Year Naturalistic Follow-Up Study
ISPUB.COM The Internet Journal of Mental Health Volume 2 Number 2 Clonazepam Augmentation Of Paroxetine In The Treatment Of Panic Disorder: A One Year Naturalistic P Dannon, I Iancu, K Lowengrub, R Amiaz,
More informationPLS 506 Mark T. Imperial, Ph.D. Lecture Notes: Reliability & Validity
PLS 506 Mark T. Imperial, Ph.D. Lecture Notes: Reliability & Validity Measurement & Variables - Initial step is to conceptualize and clarify the concepts embedded in a hypothesis or research question with
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationEarl J. Soileau, MD, FSAHM Asst Professor, Family Medicine LSU HSC Medical School New Orleans at Lake Charles
Earl J. Soileau, MD, FSAHM Asst Professor, Family Medicine LSU HSC Medical School New Orleans at Lake Charles Sleep Disorders Restless Legs Syndrome (RLS) and Periodic Limb Movement Disorder (PLMD) Sleep
More informationIs Topical Clonazepam More Effective Than Oral Clonazepam in Treatment of Burning Mouth Syndrome (BMS)?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2014 Is Topical Clonazepam More Effective
More informationPrescribing for people with a personality disorder. POMH-UK QIP 12b
Prescribing for people with a personality disorder POMH-UK QIP 12b Personality disorder Personality disorders are a heterogeneous group of conditions which vary greatly in their severity Characterised
More informationLiver Transplantation for Alcoholic Liver Disease: A Survey of Transplantation Programs in the United States
Liver Transplantation for Alcoholic Liver Disease: A Survey of Transplantation Programs in the United States James E. Everhart* and Thomas P. Beresford A lcoholic liver disease (ALD) is one of the most
More informationDocument Title Pharmacological Management of Generalised Anxiety Disorder
Document Title Pharmacological Management of Generalised Anxiety Disorder Document Description Document Type Policy Service Application Trust Wide Version 1.1 Policy Reference no. POL 201 Lead Author(s)
More informationLearning Objectives. Management of Insomnia. Impact of Chronic Insomnia. Insomnia: Definitions. Measurement of Goals. Goals of Therapy 9/29/2017
Learning Objectives Characterize insomnia and its negative effects Management of Insomnia Discuss the goals of treatment Summarize guidelines of management of insomnia including non-pharmacologic and pharmacologic
More informationStandard of Practice for Prescribing Opioids (Excluding Cancer, Palliative, and End-of-Life Care)
Standard of Practice for Prescribing Opioids (Excluding Cancer, Palliative, and End-of-Life Care) Preamble This Standard establishes the standards of practice and ethical requirements of all physicians
More informationINDEX. Group psychotherapy, described, 97 Group stimulus control, 29-47; see also Stimulus control (group setting)
Index Abdominal breathing, 70; see also Breathing; Relaxation therapy Activation, sleep drive/responsivity, 6-9 Age level; see also Elderly circadian rhythms and, 68-69 delayed sleep phase syndrome and,
More informationSupplementary Online Content 2
Supplementary Online Content 2 Bieleninik Ł, Geretsegger M, Mössler K, et al; TIME-A Study Team. Effects of improvisational music therapy vs enhanced standard care on symptom severity among children with
More informationNBPDP Drug Utilization Review Process Update
Bulletin # 802 December 1, 2010 NBPDP Drug Utilization Review Process Update The New Brunswick Prescription Drug Program (NBPDP) employs a Drug Utilization Review (DUR) process which identifies, investigates
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationMantel-Haenszel Procedures for Detecting Differential Item Functioning
A Comparison of Logistic Regression and Mantel-Haenszel Procedures for Detecting Differential Item Functioning H. Jane Rogers, Teachers College, Columbia University Hariharan Swaminathan, University of
More informationNIH Public Access Author Manuscript Psychiatry Clin Neurosci. Author manuscript; available in PMC 2010 November 1.
NIH Public Access Author Manuscript Published in final edited form as: Psychiatry Clin Neurosci. 2003 October ; 57(5): 542 544. An Open Pilot Study of Gabapentin vs. Trazodone to Treat Insomnia in Alcoholic
More informationTREATMENT OF PATIENTS DESIGNATED BY FAMILY
This report examines the role of the family doctor as related to the treatment of mental and emotional disorders in medical group practice prior to the introduction of a mental health center. The findings
More informationChapter 3. Psychometric Properties
Chapter 3 Psychometric Properties Reliability The reliability of an assessment tool like the DECA-C is defined as, the consistency of scores obtained by the same person when reexamined with the same test
More informationCognitive Behavioral Therapy for Insomnia. Melanie K. Leggett, PhD, CBSM Duke University Medical Center
Cognitive Behavioral Therapy for Insomnia Melanie K. Leggett, PhD, CBSM Duke University Medical Center Disclosures I have no relevant financial relationship with the manufacturers of any commercial products
More informationThe Short NART: Cross-validation, relationship to IQ and some practical considerations
British journal of Clinical Psychology (1991), 30, 223-229 Printed in Great Britain 2 2 3 1991 The British Psychological Society The Short NART: Cross-validation, relationship to IQ and some practical
More informationClinical Trial Synopsis TL , NCT#
Clinical Trial Synopsis, NCT#00492011 Title of Study: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Ability of Ramelteon 1 mg, 4 mg, and 8 mg to Alleviate the Insomnia
More informationRunning Head: ADVERSE IMPACT. Significance Tests and Confidence Intervals for the Adverse Impact Ratio. Scott B. Morris
Running Head: ADVERSE IMPACT Significance Tests and Confidence Intervals for the Adverse Impact Ratio Scott B. Morris Illinois Institute of Technology Russell Lobsenz Federal Bureau of Investigation Adverse
More informationCamouflage for Medical Practice or Real Assistance?
Camouflage for Medical Practice or Real Assistance? Colin Downes-Grainger September 11, 2009 Stopping Long-Term Benzodiazepines and Z Drugs - A sample letter This is a sample letter from the web that has
More informationIt s All Relative: How Presentation of Information To Patients Influences Their Decision-Making
MUMJ Original Research 15 ORIGINAL RESEARCH It s All Relative: How Presentation of Information To Patients Influences Their Decision-Making Mohit Bhandari, MD, MSc Vikas Khera, BSc Jaydeep K. Moro, MD
More informationExpectation and the Blood-Pressure-Lowering Effects of Relaxation
Expectation and the Blood-Pressure-Lowering Effects of Relaxation W. STEWART AGRAS, MD, MICHAEL HORNE, MD, AND C. BARR TAYLOR, MD In a study of the blood-pressure-lowering effects of relaxation training
More informationSummary ID#236 Clinical Study Summary: Study B1Y-MC-HCCJ
CT Registry ID#236 Page 1 Summary ID#236 Clinical Study Summary: Study B1Y-MC-HCCJ Title of Study: Fluoxetine: Fluoxetine versus Placebo in Adolescent Depressed Patients Investigator(s): This single-center
More informationTreating Insomnia in Primary Care. Judith R. Davidson Ph.D., C. Psych. Kingston Family Health Team
Treating Insomnia in Primary Care Judith R. Davidson Ph.D., C. Psych. Kingston Family Health Team jdavidson@kfhn.net Disclosure statement Nothing to disclose A ruffled mind makes a restless pillow. ~ Charlotte
More informationU.S. 1 February 22, 2013
U.S. 1 February 22, 2013 A Placebo-controlled, Randomized, Blinded, Dose Finding Phase 2 Pilot Safety Study of MDMA-assisted Therapy for Social Anxiety in Autistic Adults Study Code: MAA-1 Sponsor: Multidisciplinary
More informationExcessive Daytime Sleepiness Associated with Insufficient Sleep
Sleep, 6(4):319-325 1983 Raven Press, New York Excessive Daytime Sleepiness Associated with Insufficient Sleep T. Roehrs, F. Zorick, J. Sicklesteel, R. Wittig, and T. Roth Sleep Disorders and Research
More informationStatistical Analysis August, 2002
Self Discovery Assessment Statistical Analysis August, 2002 An Independent Study By: Jerry MacDaid 2724 SW 14th Drive Gainesville, Florida 32608 Report on the Do What You Are assessment This report summarizes
More informationGoal: To become familiar with the methods that researchers use to investigate aspects of causation and methods of treatment
Goal: To become familiar with the methods that researchers use to investigate aspects of causation and methods of treatment Scientific Study of Causation and Treatment Methods for studying causation Case
More informationPatterns of Sleepiness in Various Disorders of Excessive Daytime Somnolence
Sleep, 5:S165S174 1982 Raven Press, New York Patterns of Sleepiness in Various Disorders of Excessive Daytime Somnolence F. Zorick, T. Roehrs, G. Koshorek, J. Sicklesteel, *K. Hartse, R. Wittig, and T.
More informationSUBOXONE Film, SUBOXONE Tablets, and SUBUTEX Tablets. Risk Evaluation and Mitigation Strategy (REMS) Program
SUBOXONE Film, SUBOXONE Tablets, and SUBUTEX Tablets Risk Evaluation and Mitigation Strategy (REMS) Program Office-Based Buprenorphine Therapy for Opioid Dependence: Important Information for Prescribers
More informationStudy Center(s): The study was conducted at 39 study sites in Japan.
SYNOPSIS Issue Date: 20 NOVEMBER 2012 Name of Sponsor/Company Janssen Pharmaceutical K. K. Name of Finished Product CONCERTA Name of Active Ingredient(s) Methylphenidate HCl Protocol No.: JNS001-JPN-A01
More informationUMDNJ School of Public Health. Tobacco Dependence Clinic. Annual Report: 2003
UMDNJ School of Public Health Tobacco Dependence Clinic Annual Report: 2003 January 1, 2003 December 31, 2003 2 Tobacco Dependence Clinic at UMDNJ-School of Public Health: Summary Report 2001-2003 Introduction
More informationRecent developments for combining evidence within evidence streams: bias-adjusted meta-analysis
EFSA/EBTC Colloquium, 25 October 2017 Recent developments for combining evidence within evidence streams: bias-adjusted meta-analysis Julian Higgins University of Bristol 1 Introduction to concepts Standard
More informationPsychotropic Medication. Including Role of Gradual Dose Reductions
Psychotropic Medication Including Role of Gradual Dose Reductions What are they? The phrase psychotropic drugs is a technical term for psychiatric medicines that alter chemical levels in the brain which
More informationEFFECTS OF BENZODIAZEPINES ON SLEEP AND WAKEFULNESS
Br. J. clin. Pharmac. (1981), 11, 31S-3S EFFECTS OF BENZODIAZEPINES ON SLEEP AND WAKEFULNESS Sleep Disorders and Research Center, Henry Ford Hospital, Detroit, Michigan The differential effects of short
More informationAre psychological treatments of panic disorder efficacious?
Are psychological treatments of panic disorder efficacious? Peter Wilhelm 7.3.2018 PD Dr. Peter Wilhelm, Spring 2018 1 Efficacy of Behavioral Treatment of Panic Disorder First randomised controlled trial
More informationThe Current Status of Treatment for Anorexia Nervosa and Bulimia Nervosa
The Current Status of Treatment for Anorexia Nervosa and Bulimia Nervosa David B. Herzog Martin B. Keller Michael Strober Christine Yeh Sung-Yun Pai (Accepted 1 March 1991) A survey investigating the current
More informationONLINE DATA SUPPLEMENT - ASTHMA INTERVENTION PROGRAM PREVENTS READMISSIONS IN HIGH HEALTHCARE UTILIZERS
R2 (REVISED MANUSCRIPT BLUE 200208-877OC) ONLINE DATA SUPPLEMENT - ASTHMA INTERVENTION PROGRAM PREVENTS READMISSIONS IN HIGH HEALTHCARE UTILIZERS Mario Castro, M.D., M.P.H. Nina A. Zimmermann R.N. Sue
More informationDepressive disorders are common in primary care,
Do Clinician and Patient Adherence Predict Outcome in a Depression Disease Management Program? Catherine J. Datto, MD, Richard Thompson, PhD, David Horowitz, MD, Maureen Disbot, RN, Hillary Bogner, MD,
More informationCRITICALLY APPRAISED PAPER (CAP)
CRITICALLY APPRAISED PAPER (CAP) FOCUSED QUESTION What are the observed effects on pain and fatigue when comparing two occupational therapy activity-pacing interventions in adults with osteoarthritis?
More informationThis is because the situation is demystified and the element of fear of the unknown is eliminated.
This is more or less along the lines of the strategies we have already discussed for stress. These include common sense measures such as engaging in healthy lifestyle activities: exercising, eating well,
More informationA Modified Method for Scoring Slow Wave Sleep of Older Subjects
Sleep, 5(2):195-199 1982 Raven Press, New York A Modified Method for Scoring Slow Wave Sleep of Older Subjects Wilse B. Webb and Lewis M. Dreblow Department of Psychology, University of Florida, Gainesville,
More informationSUBJECTS AND METHODS STUDY 1
INTRODUCTION Through the ages people have searched for substances and dietary supplements that affect sexual drive or desire. A number of remedies have been developed and tried. For instance the rhinoceros
More information11. Psychopharmacological Intervention
11. Psychopharmacological Intervention 11.1 Goals of Psychopharmacology The goal of psychopharmacology is to ensure that patients with more severe forms of depression and those who fail to benefit adequately
More informationSilent Partners: The Wives of Sleep Apneic Patients
Sleep 10(3):244-248, Raven Press, New York 1987, Association of Professional Sleep Societies Silent Partners: The Wives of Sleep Apneic Patients Rosalind D. Cartwright and Sara Knight Rush-Presbyterian-St.
More informationZopiclone Orion. Date: , Version 1.2 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN
Zopiclone Orion Date: 16-11-2016, Version 1.2 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Insomnia (i.e. sleeplessness) is a common
More informationAnalysis of Confidence Rating Pilot Data: Executive Summary for the UKCAT Board
Analysis of Confidence Rating Pilot Data: Executive Summary for the UKCAT Board Paul Tiffin & Lewis Paton University of York Background Self-confidence may be the best non-cognitive predictor of future
More informationNon-Randomized Trials
Non-Randomized Trials ADA Research Toolkit ADA Research Committee 2011 American Dietetic Association. This presentation may be used for educational purposes Learning Objectives At the end of this presentation
More informationLearning Objectives 9/9/2013. Hypothesis Testing. Conflicts of Interest. Descriptive statistics: Numerical methods Measures of Central Tendency
Conflicts of Interest I have no conflict of interest to disclose Biostatistics Kevin M. Sowinski, Pharm.D., FCCP Last-Chance Ambulatory Care Webinar Thursday, September 5, 2013 Learning Objectives For
More informationClinical risk management in community pharmacy - Henk Buurma SUMMARY
SUMMARY Summary This thesis starts with an introduction (Chapter 1) in which an overview of the recent history of community pharmacy practice is presented, and in which we elaborate on the evolving role
More information9/4/2013. Decision Errors. Hypothesis Testing. Conflicts of Interest. Descriptive statistics: Numerical methods Measures of Central Tendency
Conflicts of Interest I have no conflict of interest to disclose Biostatistics Kevin M. Sowinski, Pharm.D., FCCP Pharmacotherapy Webinar Review Course Tuesday, September 3, 2013 Descriptive statistics:
More informationTechnical Specifications
Technical Specifications In order to provide summary information across a set of exercises, all tests must employ some form of scoring models. The most familiar of these scoring models is the one typically
More informationInsomnia Treatment in Brief
Insomnia Treatment in Brief Project ECHO May 7, 2015 Jonathan Emens, M.D. Associate Professor, Departments of Psychiatry and Internal Medicine Oregon Health & Science University Staff Physician and Sleep
More informationCognitive Behavioral Therapy for Chronic Insomnia: State of the Science Versus Current Clinical
Running Title: Cognitive Behavioral Therapy for Chronic Insomnia Cognitive Behavioral Therapy for Chronic Insomnia: State of the Science Versus Current Clinical Practices This article was published online
More informationInsomnia Agents (Sherwood Employer Group)
Insomnia Agents (Sherwood Employer Group) BCBSKS will review Prior Authorization requests Prior Authorization Form: https://www.bcbsks.com/customerservice/forms/pdf/priorauth-6058ks-st-ippi.pdf Link to
More informationPOLYPHARMACY : FOR AND AGAINST NZMA GP CONFERENCE 2012 PSYCHOPHARMACOLOGY SERIES. Guna Kanniah Waikato Hospital
POLYPHARMACY : FOR AND AGAINST NZMA GP CONFERENCE 212 PSYCHOPHARMACOLOGY SERIES Guna Kanniah Waikato Hospital POLYPHARMACY FIVE REASONS FOR POLYPHARMACY 1. To treat a concomitant disorder 2. To treat an
More informationAN INTEGRATED APPROACH TO BENZODIAZEPINE DISCONTINUATION: SHARED MEDICAL APPOINTMENTS FOR VETERANS CO-PRESCRIBED OPIOIDS AND BENZODIAZEPINES
AN INTEGRATED APPROACH TO BENZODIAZEPINE DISCONTINUATION: SHARED MEDICAL APPOINTMENTS FOR VETERANS CO-PRESCRIBED OPIOIDS AND BENZODIAZEPINES Elizabeth (Betsy) Crowe, PhD Lucille J. Carriere, PhD Objectives
More informationMental Illness and African- Americans: Does Stigma Affect Mental Health Treatment
Session # H4b Mental Illness and African- Americans: Does Stigma Affect Mental Health Treatment Daroine Jean-Charles, MD, Faculty Michele S. Smith, PhD, Faculty, Director of Collaborative Care Wellstar
More informationExamining Effective Navigational Learning Strategies for the Visually Impaired
Examining Effective Navigational Learning Strategies for the Visually Impaired Jeremy R. Donaldson Department of Psychology, University of Utah This study focuses on navigational learning strategies and
More informationFriend or Foe? Review of the Regulations & Benefits: Risk Profiles of the Benzodiazepines
Friend or Foe? Review of the Regulations & Benefits: Risk Profiles of the Benzodiazepines Program Learning Objectives At the conclusion of the activity, participants should be able to: Have a basic understanding
More informationVO- PMHP Treatment Guideline 102: Electroconvulsive Therapy (ECT)
VO- PMHP Treatment Guideline 102: Electroconvulsive Therapy (ECT) Diagnostic Guidelines: Introduction: Electroconvulsive Therapy has been in continuous use for more than 60 years. The clinical literature
More informationGeneral practitioners and hypnotic prescribing: attitudes, perceptions and opportunities to reduce prescribing in primary care
General practitioners and hypnotic prescribing: attitudes, perceptions and opportunities to reduce prescribing in primary care A N Siriwardena, University of Lincoln Tanefa Apekey, Lincolnshire Teaching
More informationThe Prescription Review Program and College Expectations. Dr. Rashmi Chadha MBChB MScCH CCFP MRCGP Dip. ABAM
The Prescription Review Program and College Expectations Dr. Rashmi Chadha MBChB MScCH CCFP MRCGP Dip. ABAM April 28, 2017 Disclosure Relationship with commercial interests: None Professional roles: Addictions
More informationBehavioural disabilities in psychogeriatric patients and residents of old people's homes
Journal of Epidemiology and Community Health, 1980, 34, 106-110 Behavioural disabilities in psychogeriatric patients and residents of old people's homes C. J. GILLEARD From the Department of Psychiatry,
More informationChapter V Depression and Women with Spinal Cord Injury
1 Chapter V Depression and Women with Spinal Cord Injury L ike all women with disabilities, women with spinal cord injury (SCI) may be at an elevated risk for depression due to the double jeopardy of being
More informationEstimates of the Reliability and Criterion Validity of the Adolescent SASSI-A2
Estimates of the Reliability and Criterion Validity of the Adolescent SASSI-A 01 Camelot Lane Springville, IN 4746 800-76-056 www.sassi.com In 013, the SASSI Profile Sheets were updated to reflect changes
More informationClinical audit for occupational therapy intervention for children with autism spectrum disorder: sampling steps and sample size calculation
DOI 10.1186/s13104-015-1247-0 CORRESPONDENCE Open Access Clinical audit for occupational therapy intervention for children with autism spectrum disorder: sampling steps and sample size calculation Scott
More informationDefense mechanisms and symptom severity in panic disorder
ACTA BIOMED 2010; 81: 30-34 Mattioli 1885 O R I G I N A L A R T I C L E Defense mechanisms and symptom severity in panic disorder Marco Fario, Sonja Aprile, Chiara Cabrino, Carlo Maggini, Carlo Marchesi
More informationPerception of sleep in the elderly
Norwegian Journal of Epidemiology 1998; 8 (2): 183-187 183 Perception of sleep in the elderly Ståle Pallesen, Inger Hilde Nordhus and Geir Høstmark Nielsen Departement of Clinical Psychology, University
More informationINDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER Volume: Page:
SYNOPSIS Protocol No.: TOPMAT-MIG-303 EudraCT No.: 2005-000321-29 Title of Study: A double-blind, randomised, placebo-controlled, multicentre study to investigate the efficacy and tolerability of in prolonged
More informationPeriodic Leg Movement, L-Dopa, 5-Hydroxytryptophan, and L-Tryptophan
Sleep 10(4):393-397, Raven Press, New York 1987, Association of Professional Sleep Societies Short Report Periodic Leg Movement, L-Dopa, 5-Hydroxytryptophan, and L-Tryptophan C. Guilleminault, S. Mondini,
More informationDrug prescribing by GPs in Wales and in England
Journal of Epidemiology and Community Health, 1980, 34, 119-123 Drug prescribing by GPs in Wales and in England DEE A. JONES, P. M. SWEETNAM, AND P. C. ELWOOD From the MRC Epidemiology Unit, Cardiff SUMMARY
More informationRandomized Controlled Trial
Randomized Controlled Trial Training Course in Sexual and Reproductive Health Research Geneva 2016 Dr Khalifa Elmusharaf MBBS, PgDip, FRSPH, PHD Senior Lecturer in Public Health Graduate Entry Medical
More informationObjectives. Disclosure. APNA 26th Annual Conference Session 2017: November 8, Kurtz 1. The speaker has no conflicts of interest to disclose
Christine Kurtz, DNP, PMHCNS BC Valparaiso University Disclosure The speaker has no conflicts of interest to disclose Objectives The learner will Describe the rationale for and five therapies of CBT I
More informationsodium oxybate, 500mg/ml oral solution (Xyrem) No. (246/06) UCB Pharma Ltd
Scottish Medicines Consortium Resubmission sodium oxybate, 500mg/ml oral solution (Xyrem) No. (246/06) UCB Pharma Ltd 10 August 2007 The Scottish Medicines Consortium has completed its assessment of the
More informationTHE SEVEN SINS OF PSYCHOPHARMACOLOGY. Carl Salzman MD Montreal, 2011
THE SEVEN SINS OF PSYCHOPHARMACOLOGY Carl Salzman MD Montreal, 2011 HOW DO CLINICIANS LEARN ABOUT PSYCHOTROPIC DRUGS? Reading the literature Continuing medical education Colleagues Clinical experience
More information2008AARPDriverSafety Program CourseEvaluation
2008AARPDriverSafety Program CourseEvaluation December2008 2008 AARP Driver Safety Program Course Evaluation Report Prepared by Laura Skufca, M.A. Copyright 2008 AARP Knowledge Management 601 E Street,
More informationANXIETY A brief guide to the PROMIS Anxiety instruments:
ANXIETY A brief guide to the PROMIS Anxiety instruments: ADULT PEDIATRIC PARENT PROXY PROMIS Pediatric Bank v1.0 Anxiety PROMIS Pediatric Short Form v1.0 - Anxiety 8a PROMIS Item Bank v1.0 Anxiety PROMIS
More information